利用禽致病性大肠杆菌衍生的膜囊泡作为家禽大肠杆菌病的交叉保护性亚单位疫苗候选物

核心信息

• 论文英文标题: Exploiting membrane vesicles (MVs) derived from avian pathogenic Escherichia coli as a cross-protective subunit vaccine candidate against avian colibacillosis
• 期刊: POULTRY SCI
• 发表年份: 2024
• DOI: 10.1016/j.psj.2024.104148
• PMID/PMCID: 39142031; PMC11379662

研究概览

Here, we evaluated the immunoprotective efficacy of MVs derived from the LPS low-expressed APEC strain FY26ΔmsbB, which was an APEC mutant strain with a deletion of the msbB gene. These findings suggest that MVs generated from the LPS low-expressed APEC strain FY26ΔmsbB represent a novel and empirically validated subunit vaccine for the prevention and control of infections by various APEC serotypes.

核心发现

Avian pathogenic Escherichia coli (APEC) is a notable pathogen that frequently leads to avian colibacillosis, posing a substantial risk to both the poultry industry and public health.

The commercial vaccines against avian colibacillosis are primarily inactivated vaccines, but their effectiveness is limited to specific serotypes.

Recent advances have highlighted bacterial membrane vesicles (MV) as a promising candidate in vaccine research.

How to produce bacterial MVs vaccines on a large scale is a significant challenge for the industrialization of MVs.

Echo Biotech 角色

大肠杆菌来源囊泡NTA鉴定

关联平台: Exoomics®

关联服务与能力: EV Basic Characterization (TEM/NTA/WB)

关联产品或试剂: 无明确产品引用

参考文献

原始论文: Exploiting membrane vesicles (MVs) derived from avian pathogenic Escherichia coli as a cross-protective subunit vaccine candidate against avian colibacillosis Poultry Science. 2024. DOI: 10.1016/j.psj.2024.104148. PMID/PMCID: 39142031; PMC11379662.